Sharma Mini, Kumar Neeraj, Saha Subhas, Suri Vanita, Prasad G R, Srinivasan Radhika, Pal Arnab
Post Graduate Institute of Medical Education and Research, OBG.
Dr Rajendra Prasad Government Medical College.
Afr Health Sci. 2024 Dec;24(4):120-128. doi: 10.4314/ahs.v24i4.16.
Ovarian cancer is the seventh most common cancer in women and is ranked third among gynaecological malignancies after cervical and uterine cancers. Prospective studies have failed to establish a definite screening programme based on tumour markers or ultrasonography.
To evaluate potential role of Human Epididymis protein 4 (HE4) as a biomarker for diagnosis of various ovarian malignancies in premenopausal age group, either alone or as a part of diagnostic algorithm like Risk of Malignancy Algorithm (ROMA) and to analyse if it has any advantage over Cancer Antigen 125 (CA125) or Risk of Malignancy Index (RMI).
It was an observational cross-sectional study which included 100 premenopausal women having ovarian mass and underwent surgery. The diagnostic performances of CA125, HE4, ROMA score and RMI for ovarian cancer were evaluated.
Postoperative histopathology confirmed 30% (n=30) women to have malignant ovarian tumors. According to receiver operating characteristic (ROC) analysis; area under curve (AUC) was maximum for ROMA (0.791) followed by HE4 (0.784), RMI (0.750) and CA125 (0.715).
HE4 is not superior to CA125 but, it can be used in series or as part of diagnostic algorithm (ROMA) along with CA125 to get higher diagnostic accuracy for premenopausal women.
卵巢癌是女性中第七大常见癌症，在妇科恶性肿瘤中仅次于宫颈癌和子宫癌，位居第三。前瞻性研究未能基于肿瘤标志物或超声检查建立明确的筛查方案。
评估人附睾蛋白4（HE4）作为生物标志物在绝经前年龄组各种卵巢恶性肿瘤诊断中的潜在作用，单独使用或作为恶性风险算法（ROMA）等诊断算法的一部分，并分析其是否比癌抗原125（CA125）或恶性风险指数（RMI）具有任何优势。
这是一项观察性横断面研究，纳入了100名有卵巢肿块并接受手术的绝经前女性。评估了CA125、HE4、ROMA评分和RMI对卵巢癌的诊断性能。
术后组织病理学证实30%（n = 30）的女性患有恶性卵巢肿瘤。根据受试者工作特征（ROC）分析；曲线下面积（AUC）以ROMA最大（0.791），其次是HE4（0.784）、RMI（0.750）和CA125（0.715）。
HE4并不优于CA125，但它可以与CA125串联使用或作为诊断算法（ROMA）的一部分，以提高绝经前女性的诊断准确性。
